Entrada Therapeutics Reports $44.1 Million Net Loss and Declining Collaboration Revenue in Latest Quarter

Entrada Therapeutics, Inc. reported significant financial challenges in its latest quarterly filing, with a net loss of $44.1 million for the three months ended September 30, 2025, compared to a loss of $14.0 million in the same period last year. The company's collaboration revenue plummeted to $1.6 million from $19.6 million year-over-year, primarily due to reduced costs associated with its partnership with Vertex Pharmaceuticals, as research activities for the VX-670 candidate were largely completed in the first quarter of 2025. For the nine months ending September 30, 2025, total collaboration revenue was $24.1 million, down from $173.4 million in the prior year, reflecting a decrease of $149.3 million.

Operating expenses also increased, with research and development costs rising to $38.4 million in Q3 2025 from $31.3 million in Q3 2024, driven by heightened spending on the company's Duchenne muscular dystrophy (DMD) programs. General and administrative expenses saw a smaller increase, totaling $10.3 million compared to $10.0 million in the previous year. The total operating expenses for the quarter reached $48.7 million, up from $41.2 million in the prior year, leading to a loss from operations of $47.1 million, a significant increase from the $21.7 million loss reported in Q3 2024.

In terms of strategic developments, Entrada has made progress in its clinical pipeline, particularly with its EEV™ therapeutics aimed at treating DMD. The company has fully enrolled the first cohort of patients in the Phase 1/2 clinical trial for ENTR-601-44 and has initiated dosing for ENTR-601-45. Additionally, Entrada filed for UK regulatory clearance for ENTR-601-50 in Q3 2025 and plans to submit for EU clearance in the second half of 2026. The company also reported a workforce reduction of approximately 20% in April 2025, incurring a charge of $1.9 million, primarily related to severance payments.

As of September 30, 2025, Entrada had cash, cash equivalents, and marketable securities totaling $326.8 million, which the company believes will be sufficient to fund operations into the third quarter of 2027. However, the company anticipates needing additional financing to support ongoing operations and development efforts, as it continues to incur significant operating losses. The outlook remains cautious, with the company emphasizing the need for substantial additional funding to advance its therapeutic candidates through clinical development and to establish a commercialization infrastructure if any candidates receive regulatory approval.